The Efficacy and Safety of Negative-Pressure Wound Therapy Combined With Platelet-Rich Plasma in Chronic Refractory Wounds: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

被引:0
作者
Hao, Ran [1 ]
Luo, Mao [2 ]
Xiao, Yanting [3 ]
Li, Jing [1 ]
Lv, Xinyue [1 ]
Peng, Yumei [1 ]
Wu, Yuxuan [1 ]
Shen, Yan [1 ]
Jiang, Wei [1 ]
机构
[1] Deyang Peopless Hosp, Dept Orthoped, Deyang, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Rehabil, Nanchang, Jiangxi, Peoples R China
关键词
chronic refractory wound; meta-analysis; negative-pressure wound therapy; platelet-rich plasma; wound healing; wounds and injuries; CYTOKINE LEVELS; EXPRESSION; MECHANISM; QUALITY; ROLES; GRADE;
D O I
10.1002/hsr2.70205
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and aims: Chronic refractory wound is a disease that seriously impairs the quality of life of patients. Negative pressure wound therapy and platelet-rich plasma are commonly used to treat various types of wounds. Further research is necessary to explore the efficacy and safety of the combination of negative pressure wound therapy and platelet-rich plasma in treating chronic refractory wounds. Methods: PubMed, Web of Science, EMBASE, Cochrane, CINAHL, CNKI, Sino Med, and Wanfang Med Online up until March 2024 were searched(PROSPERO No. CRD42024507963). Two investigators screened literature according to inclusion and exclusion criteria, evaluated bias and certainty of evidence using RoB 2.0 and GRADE. Stata 12.0 was used to analyze the data. Results: A total of 35 randomized controlled trials involving 2495 participants were included. 34 studies were assessed as having some concerns, and 1 study as having high risk in the risk of bias assessment. The results of meta-analysis showed that effective rate (RR1.23, 95% CI [1.17, 1.30], p < 0.001; I-2 = 44.7%, p = 0.013), healing time (WMD-9.32, 95% CI [-10.60, -8.03], p < 0.001; I-2 = 91.00%, p < 0.001), healing rate (RR1.76, 95% CI [1.50, 2.07], p < 0.001; I-2 = 62.6%, p < 0.001), positive rate of bacterial(RR0.25, 95% CI [0.15, 0.40], p < 0.001; I-2 = 0%, p = 0.841), pain score (WMD-1.43, 95% CI [-2.14, -0.72], p < 0.001; I-2 = 96.5%, p < 0.001), incidence of complications (RR0.45, 95% CI [0.30, 0.68], p < 0.001; I-2 = 46.3%, p = 0.098), length of hospital stay (WMD-9.88, 95% CI [-13.42, 6.34], p < 0.001; I-2 = 98.9%, p < 0.001), number of dressing changes (WMD-2.56, 95% CI [-4.28, -0.83], p = 0.004; I-2 = 98.9%, p < 0.001), white blood cell level (WMD-1.71, 95% CI [-2.00, -1.41], p < 0.001; I-2 = 33.9%, p = 0.195), c-reactive protein level (WMD-0.68, 95% CI [-1.04, -0.33], p < 0.001; I-2 = 88.8%, p < 0.001), erythrocyte sedimentation rate (WMD-6.09, 95% CI [-8.05, -4.13], p < 0.001; I-2 = 13%, p = 0.32), score of vancouver scar scale (WMD-1.78, 95% CI [-1.89, -1.66], p < 0.001; I-2 = 38.3%, p = 0.166) and preparation time of secondary repair (WMD-4.95, 95% CI [-7.03, -2.87], p < 0.001; I-2 = 84.7%, p < 0.001) had statistically significant effects. However, hospitalization costs (WMD1423.56, 95% CI [-4588.93, 7436.06], p = 0.643; I-2 = 100%, p < 0.001) had no significant difference. Conclusions: This study demonstrates that the combination of negative-pressure wound therapy and platelet-rich plasma can improve the efficacy and safety on chronic refractory wounds. Optimal parameter combinations, elucidation of pathogenesis and treatment mechanisms can be explored in the future.
引用
收藏
页数:18
相关论文
共 82 条
  • [1] A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification
    Alves, Rubina
    Grimalt, Ramon
    [J]. SKIN APPENDAGE DISORDERS, 2018, 4 (01) : 18 - 24
  • [2] Vesicular formation regulated by ERK/MAPK pathway mediates human erythroblast enucleation
    An, Chao
    Huang, Yumin
    Li, Mengjia
    Xue, Fumin
    Nie, Dingrui
    Zhao, Huizhi
    Chen, Lixiang
    Yazdanbakhsh, Karina
    Sun, Ling
    Jiang, Zhongxing
    Mohandas, Narla
    An, Xiuli
    [J]. BLOOD ADVANCES, 2021, 5 (22) : 4648 - 4661
  • [3] Anchalia M., 2020, Wounds: A Compendium of Clinical Research and Practice, V32, P84
  • [4] Biao Y., 2019, Journal of Clinical Rehabilitative Tissue Engineering Research, V23, P4181, DOI [10.3969/j.issn.2095-4344.1357, DOI 10.3969/J.ISSN.2095-4344.1357]
  • [5] Changzhu C., 2018, China Reflexolocy, V27, P42, DOI [10.19589/j.cnki.issn1004-6569.2018.22.042, DOI 10.19589/J.CNKI.ISSN1004-6569.2018.22.042]
  • [6] RETRACTED: Effect of platelet-rich plasma combined with negative pressure wound therapy in treating patients with chronic wounds: A meta-analysis (Retracted Article)
    Chen, Hao
    Xu, Tong-Jie
    Yu, Hao
    Zhu, Jun-Long
    Liu, Yong
    Yang, Lu-Pin
    [J]. INTERNATIONAL WOUND JOURNAL, 2024, 21 (04)
  • [7] Chijiao M., 2018, Shanxi Medical Journal, V47, P2180, DOI [10.3969/j.issn.0253-9926.2018.18.022, DOI 10.3969/J.ISSN.0253-9926.2018.18.022]
  • [8] Matrix metalloproteinase expression in cytokine stimulated human dermal fibroblasts
    Dasu, MRK
    Barrow, RE
    Spies, M
    Herndon, DN
    [J]. BURNS, 2003, 29 (06) : 527 - 531
  • [9] Comparison of different sources of platelet-rich plasma as treatment option for infertility-causing endometrial pathologies
    de Miguel-Gomez, Lucia
    Lopez-Martinez, Sara
    Campo, Hannes
    Frances-Herrero, Emilio
    Faus, Amparo
    Diaz, Ana
    Pellicer, Antonio
    Dominguez, Francisco
    Cervello, Irene
    [J]. FERTILITY AND STERILITY, 2021, 115 (02) : 490 - 500
  • [10] Platelet Rich Plasma in Orthopedic Surgical Medicine.
    Everts, Peter A.
    van Erp, Albert
    DeSimone, Alfred
    Cohen, Dan S.
    Gardner, Ronald D.
    [J]. PLATELETS, 2021, 32 (02) : 163 - 174